{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:49:43Z","timestamp":1789148983684,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ad.2023.05.045","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:55:03Z","timestamp":1721332503000},"page":"1020-1023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Four-case Report of Upadacitinib as an Alternative Treatment for Patients With Recalcitrant Pyoderma Gangrenosum"],"prefix":"10.1016","volume":"115","author":[{"given":"F.J.","family":"Melgosa Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garc\u00eda-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aguado V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mercader-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.05.045_bib0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum \u2013 a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.ad.2023.05.045_bib0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","article-title":"Pyoderma gangrenosum: a review of pathogenesis and treatment","volume":"14","author":"Ahn","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2023.05.045_bib0065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.abd.2020.06.014","article-title":"Pyoderma gangrenosum associated to the use of cocaine\/levamisole. Series of three cases and literature review","volume":"96","author":"Mart\u00ednez-G\u00f3mez","year":"2021","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2023.05.045_bib0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.05.045_bib0075","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","volume":"46","author":"Orfaly","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2023.05.045_bib0080","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.jtauto.2021.100099","article-title":"Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor","volume":"4","author":"Scheinberg","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.ad.2023.05.045_bib0085","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/ibd\/izz015","article-title":"Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab","volume":"25","author":"Gregory","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2023.05.045_bib0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jdcr.2020.07.035","article-title":"Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib","volume":"6","author":"Choi","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ad.2023.05.045_bib0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ibd\/izab176","article-title":"Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn's disease","volume":"28","author":"Lee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2023.05.045_bib0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ddg.14716","article-title":"Response of rheumatoid arthritis-associated pyoderma gangrenous to the JAK1 inhibitor upadacitinib","volume":"20","author":"Kooybaran","year":"2022","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024005891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024005891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T13:48:56Z","timestamp":1733147336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024005891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0001731024005891"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.05.045","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four-case Report of Upadacitinib as an Alternative Treatment for Patients With Recalcitrant Pyoderma Gangrenosum","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.05.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}